CategorySymptoms and treatments

Protecting nerves with the -imods. Is there something missing

Fingolimod is a sphingosine-1-phophaste receptor (S1PR) modulator. There are five S1PR. The immune modulating effect is mediated by S1P1R. Siponimod is an S1P1R and S1P5R selective modulator. Fingo also binds to S1P3R (this causes some of the heart related issues) and S1P4R in addition to S1P1R and S1P5R. S1P5R is found on glial cells and it has been suggested that repair and protection can occur...

B cells and MS…”It’s behind you”…Are we looking in the wrong place?

As the countdown to B cell week at Charcot Meeting (a meeting aiming at training young neurologists) occurs, I had a gripe that I had been given a miss as far as this meeting is concerned. I will be sat at home licking my wounds, as young new minds are manipulated and learn all things MS. However, what you learn depends on what you get taught. There are a series of company sponsored symposia at...

Class Action…..Is CD20 depletion an IRT?

Recently ProfG has been talking about immune reconsitution therapies and it has been asked if ocrelizumab is an IRT? This is important to know because it says that you would not have to dose as frequently and whilst this may make a dint in the coffers of the manufacturer, it could mean an improvement in the risk:benefit profile for you…..if this is true. No one wants an EMA or FDA...

One for ProfK, as cladribine manufactureres are accused of making money

Cladribine repurposed in multiple sclerosis: making a fortune out of a generic drug. Buiter HJC, Derijks L, Mulder CJJ. Eur J Hosp Pharm. 2019 Sep;26(5):246-247 We have discussed this before and it is clear that the cost of MS drugs, bear no real relationship to their manufacturing costs. MS trials are very expensive and these costs need to be re-couped. Now, I am not going to defend the...

ProfK goes fishing. Blood cells tell you nothing about alemtuzumab…especially if you look in the wrong way!

ProfK has many talents, but I bet you didn’t know he is a keen angler. Now, you won’t find him in Clarme Common with his tackle out at the fish pond…which is a good thing as there are laws against that sort of behaviour :-), but as a card-carrying veggie, you wouldn’t have thought that he likes to fish…… for mice. But that is just what has happened. The new...

Your race in MS

Race, ethnicity, creed – all architectural descriptors, some complex, others less so, depending on your perspective. When it comes to illnesses however, you are largely referencing race (the inheritance of your DNA) and ethnicity (the branch of race that your DNA occupies). We may be different in a number of ways, but our illnesses are a great equalizer. There is no such thing as race...

Inhibition of B cell survival factors does not inhibit MS

You know me, I love to write papers, pharma seem to hate it, so I say to them just give me the data and save yourself a few grand paying medical writers. OK, they can’t dictatate what I am going to write, but the data generally speaks for itself. They just don’t want to let the data out:-(. After the excitement of HSCT- thursday…. and friday, its back to reality. This post...

Telling signs

Despite advances in MRI, the diagnosis of MS is hard for the non-specialist. A Swiss study recently found that the delay in MS diagnosis is more than 2 years in 40% of PwMS. Surprised? You should be, because according to this study by 2016-2017 the delay in diagnosis had only improved by half as much since the year 2000! What is not surprising, however, is that in a majority of instances this...

Guidelines for Managing Thyroid dysfunction

This post is for any health-professions who read the blog. This gives guidelines for managing thyroid problems notably after alemtuzumab 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy. Muller I, Moran C, Lecumberri B, Decallonne B, Robertson N, Jones J, Dayan CM. Eur Thyroid J. 2019 Jul;8(4):173-185. Thyroid...

Is this the next treatment for MS…If you have psychosis?

We all have heard about BioRXiV (Bioarchive), where people can deposit their preprints before publication on a journal. Now there is not MedRXiv (Medarchive). All that needs to be done is link this up to Pubmed and we can cut out the middle man (publisher). A free archive that is open access and you get rid of the impact factor and the publishing mess in one easy swoop. What’s not to like...

Translate

Categories

Recent Posts

Recent Comments

Archives